Elite in Dementia

Craig W. Ritchie

Morningside Terrace, 
Edinburgh, SCT, GB 
Elite in Dementia
Morningside Terrace, 
Edinburgh, SCT, GB 
OverviewLocationsClinical Research

Overview

Craig Ritchie practices in Edinburgh, United Kingdom. Mr. Ritchie is rated as an Elite expert by MediFind in the treatment of Dementia. His top areas of expertise are Dementia, Alzheimer's Disease, Developmental Dysphasia Familial, and Memory Loss.

His clinical research consists of co-authoring 243 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 204 articles and participated in 3 clinical trials in the study of Dementia.

Gender
Male

Locations

Morningside Terrace, Edinburgh, SCT, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease
A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Other, Biological
Study Drugs: ACI-35.030 Anti-Tau Vaccine, JACI-35.054 Anti-Tau Vaccine
Study Phase: Phase 1/Phase 2
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)
European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)
Enrollment Status: Terminated
Publish Date: March 31, 2020
View 2 Less Clinical Trials

243 Total Publications

GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy.
GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy.
Journal: Research square
Published: June 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ritchie's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile